MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non
US biotech Moderna has completed the installation of its clinical laboratories at its new R&D facility in the UK dedicated to the discovery of new mRNA vaccines and th
The European Patent Office has said it has invalidated a patent held by Moderna on mRNA-based COVID-19 vaccines, the latest development in an increasingly acrimonious disp
Shares in Moderna have been under pressure after the company posted a third-quarter loss of $3.6 billion and a steep fall in COVID-19 vaccine sales, although it still thin
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year
